Under construction – not a live service
Sign in

2024-519060-40-00Not yet recruitingPhase 1

A study of safety, feasibility and immunologic response of transfering tumor infiltrating lymphocytes with or without dendritic cell vaccination in patients with metastatic melanoma

Source: EU CTIS (euclinicaltrials.eu) · Last updated 23 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open

Next steps

Status (registry)
Not yet recruiting
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
20 (estimated)
First submitted
22 Jan 2025
Start date
5 Apr 2013
Lead sponsor
Karolinska University Hospital
Diseases
Melanoma
EU CT number
2024-519060-40-00
EudraCT number
2012-000450-63

What you commit to

  • Study type: Interventional · Phase 1
  • Planned participants: 20
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced melanoma that has spread, with measurable tumours in internal organs. It tests tumour infiltrating lymphocytes with or without a dendritic cell vaccine.

Age
18 years or older
Sex
All sexes can join
Disease stage
Metastatic malignant melanoma, stage 3 or 4, with measurable lesions in internal organs

Read by machine on 9 Nov 2026.

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Karolinska University HospitalSolnaSwedenNot yet recruiting

Are you the coordinator? Confirm the details

This page is information, not medical advice. Discuss any trial with your doctor.